↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Devore S) "

Search: WFRF:(Devore S)

Result 1-10 of 12

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Jukema, JW, et al. (author) Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1167-1176 Journal article (peer-reviewed)
2.	Ray, KK, et al. (author) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 2019 In: The lancet. Diabetes & endocrinology. - 2213-8595 .- 2213-8587. ; 7:8, s. 618-628 Journal article (peer-reviewed)
3.	Roe, MT, et al. (author) Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes 2019 In: Circulation. - : Ovid Technologies (Wolters Kluwer Health). - 1524-4539 .- 0009-7322. ; 140:19, s. 1578-1589 Journal article (peer-reviewed)
4.	Szarek, M, et al. (author) Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial 2019 In: Circulation. Cardiovascular quality and outcomes. - : Ovid Technologies (Wolters Kluwer Health). - 1941-7705 .- 1941-7713. ; 12:11, s. e005858- Journal article (peer-reviewed)
5.	Szarek, M, et al. (author) Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 73:4, s. 387-396 Journal article (peer-reviewed)
6.	Bittner, VA, et al. (author) Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome 2020 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 75:2, s. 133-144 Journal article (peer-reviewed)
7.	Goodman, SG, et al. (author) Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1177-1186 Journal article (peer-reviewed)
8.	Schwartz, GG, et al. (author) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome 2018 In: The New England journal of medicine. - : MASSACHUSETTS MEDICAL SOC. - 1533-4406 .- 0028-4793. ; 379:22, s. 2097-2107 Journal article (peer-reviewed)
9.	Bhatt, A. S., et al. (author) Achieving a Maximally Tolerated beta-Blocker Dose in Heart Failure Patients Is There Room for Improvement? 2017 In: Journal of the American College of Cardiology. - : Elsevier BV. - 0735-1097. ; 69:20, s. 2542-2550 Journal article (peer-reviewed)abstract Heart failure (HF) is associated with significant morbidity and mortality. Although initially thought to be harmful in HF, beta-adrenergic blockers (beta-blockers) have consistently been shown to reduce mortality and HF hospitalization in chronic HF with reduced ejection fraction. Proposed mechanisms include neurohormonal blockade and heart rate reduction. A new therapeutic agent now exists to target further heart rate lowering in patients who have been stable on a "maximally tolerated b-blocker dose," but this definition and how to achieve it are incompletely understood. In this review, the authors summarize published reports on the mechanisms by which beta-blockers improve clinical outcomes. The authors describe differences in doses achieved in landmark clinical trials and those observed in routine clinical practice. They further discuss reasons for intolerance and the evidence behind using b-blocker dose and heart rate as therapeutic targets. Finally, the authors offer recommendations for clinicians actively initiating and up-titrating b-blockers that may aid in achieving maximally tolerated doses. (C) 2017 by the American College of Cardiology Foundation.
10.	Cooper, LB, et al. (author) ASSOCIATION BETWEEN SERUM POTASSIUM LEVEL AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A COHORT STUDY FROM THE SWEDISH HEART FAILURE REGISTRY 2017 In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - 0735-1097. ; 69:11, s. 678-678 Conference paper (other academic/artistic)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-10 of 12

Refine your search

Type of publication: journal article (11); conference paper (1)

Type of content: peer-reviewed (11); other academic/artistic (1)

Author/Editor: King, M. (8); Li, Y. (8); Schmidt, E. (8); Zaman, A. (8); Zhang, Z. (8); Zhu, H. (8); show more...; Guo, Y (8); Ahmed, H. (8); Kaiser, S. (8); Nikolaev, K. (8); Schwartz, M. (8); Kumar, A. (8); Robinson, S. (8); Zheng, Y. (8); Costa, F. (8); Das, S. (8); Diaz, R. (8); Mahajan, A. (8); Davies, R (8); Aggarwal, R. (8); Andersen, K (8); Diaz, A. (8); Cohen, S. (8); Rosenberg, M. (8); Gullestad, L (8); Hong, T. (8); Kumar, P. (8); Khan, A. (8); Davis, W. (8); Aboyans, V (8); Khan, M (8); Liu, SW (8); Pandey, A (8); Sarkar, D. (8); Hoffman, D (8); Takahashi, T. (8); Marx, R. (8); Bottcher, M. (8); White, M. (8); Seferovic, P (8); Wells, T (8); Katz, A. (8); Ito, K. (8); Kobayashi-, J (8); Anderson, J. (8); Harding, S (8); Huang, L. (8); Vulic, D (8); Pearce, S (8); Gerber, J. (8); show less...

University: Karolinska Institutet (10); Uppsala University (9); University of Gothenburg (1)

Language: English (12)

Research subject (UKÄ/SCB): Medical and Health Sciences (9); Natural sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view